Literature DB >> 21499984

The immunomodulatory properties of mesenchymal stem cells.

Ilaria Marigo1, Francesco Dazzi.   

Abstract

Research on mesenchymal stem cells (MSC) has evolved rapidly during the last decade prompted by their potential use for tissue repair and immunotherapy. Not only can MSC differentiate into cells of the mesodermal lineage, but they also exhibit immunomodulatory functions depending on their interaction with cells of both innate and adaptive immune systems. Most aspects of MSC biology remain to be elucidated. It is emerging even more clearly that these cells are not always a panacea. Only the knowledge of their physiological role and their interactions with other cells will allow us to use them as a therapeutic tool.

Entities:  

Mesh:

Year:  2011        PMID: 21499984     DOI: 10.1007/s00281-011-0267-7

Source DB:  PubMed          Journal:  Semin Immunopathol        ISSN: 1863-2297            Impact factor:   9.623


  104 in total

1.  Mesenchymal progenitor cells in human umbilical cord blood.

Authors:  A Erices; P Conget; J J Minguell
Journal:  Br J Haematol       Date:  2000-04       Impact factor: 6.998

Review 2.  Bone-marrow haematopoietic-stem-cell niches.

Authors:  Anne Wilson; Andreas Trumpp
Journal:  Nat Rev Immunol       Date:  2006-02       Impact factor: 53.106

3.  Stromal cells responsible for transferring the microenvironment of the hemopoietic tissues. Cloning in vitro and retransplantation in vivo.

Authors:  A J Friedenstein; R K Chailakhyan; N V Latsinik; A F Panasyuk; I V Keiliss-Borok
Journal:  Transplantation       Date:  1974-04       Impact factor: 4.939

4.  Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting.

Authors:  Alma J Nauta; Geert Westerhuis; Alwine B Kruisselbrink; Ellie G A Lurvink; Roel Willemze; Willem E Fibbe
Journal:  Blood       Date:  2006-05-11       Impact factor: 22.113

5.  A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an Immunosuppressive MSC2 phenotype.

Authors:  Ruth S Waterman; Suzanne L Tomchuck; Sarah L Henkle; Aline M Betancourt
Journal:  PLoS One       Date:  2010-04-26       Impact factor: 3.240

6.  Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy.

Authors:  Laura S Sasportas; Randa Kasmieh; Hiroaki Wakimoto; Shawn Hingtgen; Jeroen A J M van de Water; Gayatry Mohapatra; Jose Luiz Figueiredo; Robert L Martuza; Ralph Weissleder; Khalid Shah
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-05       Impact factor: 11.205

Review 7.  Inflammation and tumor microenvironments: defining the migratory itinerary of mesenchymal stem cells.

Authors:  E Spaeth; A Klopp; J Dembinski; M Andreeff; F Marini
Journal:  Gene Ther       Date:  2008-04-10       Impact factor: 5.250

8.  Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide.

Authors:  Guangwen Ren; Liying Zhang; Xin Zhao; Guangwu Xu; Yingyu Zhang; Arthur I Roberts; Robert Chunhua Zhao; Yufang Shi
Journal:  Cell Stem Cell       Date:  2008-02-07       Impact factor: 24.633

Review 9.  Mesenchymal stem cells: an emerging tool for cancer targeting and therapy.

Authors:  Vanessa Fritz; Christian Jorgensen
Journal:  Curr Stem Cell Res Ther       Date:  2008-01       Impact factor: 3.828

10.  Treatment of experimental arthritis by inducing immune tolerance with human adipose-derived mesenchymal stem cells.

Authors:  Manuel A González; Elena Gonzalez-Rey; Laura Rico; Dirk Büscher; Mario Delgado
Journal:  Arthritis Rheum       Date:  2009-04
View more
  65 in total

1.  Linking stem cells to chromosomal instability.

Authors:  Karel H M van Wely; Carlos Martínez-A
Journal:  Oncoimmunology       Date:  2012-03-01       Impact factor: 8.110

Review 2.  Overcoming immunoregulatory plasticity of mesenchymal stem cells for accelerated clinical applications.

Authors:  Nayoun Kim; Seok-Goo Cho
Journal:  Int J Hematol       Date:  2015-12-11       Impact factor: 2.490

3.  Considerations on the harvesting site and donor derivation for mesenchymal stem cells-based strategies for diabetes.

Authors:  L Zazzeroni; G Lanzoni; G Pasquinelli; C Ricordi
Journal:  CellR4 Repair Replace Regen Reprogram       Date:  2017-09-29

4.  Preconditioned mesenchymal stem cells treat myasthenia gravis in a humanized preclinical model.

Authors:  Muriel Sudres; Marie Maurer; Marieke Robinet; Jacky Bismuth; Frédérique Truffault; Diane Girard; Nadine Dragin; Mohamed Attia; Elie Fadel; Nicola Santelmo; Camille Sicsic; Talma Brenner; Sonia Berrih-Aknin
Journal:  JCI Insight       Date:  2017-04-06

5.  Adipose tissue-derived multipotent stromal cells have a higher immunomodulatory capacity than their bone marrow-derived counterparts.

Authors:  Sara M Melief; Jaap Jan Zwaginga; Willem E Fibbe; Helene Roelofs
Journal:  Stem Cells Transl Med       Date:  2013-05-21       Impact factor: 6.940

6.  Chondrogenic differentiation increases antidonor immune response to allogeneic mesenchymal stem cell transplantation.

Authors:  Aideen E Ryan; Paul Lohan; Lisa O'Flynn; Oliver Treacy; Xizhe Chen; Cynthia Coleman; Georgina Shaw; Mary Murphy; Frank Barry; Matthew D Griffin; Thomas Ritter
Journal:  Mol Ther       Date:  2013-11-01       Impact factor: 11.454

Review 7.  Rationale for the potential use of mesenchymal stromal cells in liver transplantation.

Authors:  Morgan Vandermeulen; Céline Grégoire; Alexandra Briquet; Chantal Lechanteur; Yves Beguin; Olivier Detry
Journal:  World J Gastroenterol       Date:  2014-11-28       Impact factor: 5.742

8.  Immune-related antigens, surface molecules and regulatory factors in human-derived mesenchymal stromal cells: the expression and impact of inflammatory priming.

Authors:  Mehdi Najar; Gordana Raicevic; Hussein Fayyad-Kazan; Hussein Fayyad Kazan; Cécile De Bruyn; Dominique Bron; Michel Toungouz; Laurence Lagneaux
Journal:  Stem Cell Rev Rep       Date:  2012-12       Impact factor: 5.739

9.  Induction of mixed chimerism using combinatory cell-based immune modulation with mesenchymal stem cells and regulatory T cells for solid-organ transplant tolerance.

Authors:  Keon-Il Im; Min-Jung Park; Nayoun Kim; Jung-Yeon Lim; Hyun-Sil Park; Sung-Hee Lee; Young-Sun Nam; Eun-Sol Lee; Jung-Ho Lee; Mi-La Cho; Seok-Goo Cho
Journal:  Stem Cells Dev       Date:  2014-06-26       Impact factor: 3.272

10.  Multipotent stromal cells skew monocytes towards an anti-inflammatory interleukin-10-producing phenotype by production of interleukin-6.

Authors:  Sara M Melief; Sacha B Geutskens; Willem E Fibbe; Helene Roelofs
Journal:  Haematologica       Date:  2013-01-24       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.